Further, the cytotoxic and DNA damage effect of the IR+PARGi combination was strongly suppressed by pre-treatment with the PARP1/PARP2 inhibitor ABT-888 (PARPi; Veliparib, 10 μM) in several GSCs as well as the model glioma cell line, LN428 (Figure 1D,E, Supplementary Figure S1K–M). This evidence concerns the gene PARP1 and central nervous system cancer.